Geron slides on trial discontinuation

Geron Corp. (NASDAQ:GERN) fell $1.62 (56%) to $1.28 on Monday after discontinuing a Phase II trial of imetelstat to treat locally recurrent or metastatic breast cancer following interim data

Read the full 297 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE